Suppr超能文献

永久性粒子植入中为实现最佳前列腺剂量覆盖的同位素半衰期与前列腺水肿之间的关系。

Relationship between isotope half-life and prostatic edema for optimal prostate dose coverage in permanent seed implants.

作者信息

Villeneuve Maxime, Leclerc Ghyslain, Lessard Etienne, Pouliot Jean, Beaulieu Luc

机构信息

Département de Radio-Oncologie et Centre de Recherche en Cancérologie, Hôtel-dieu de Québec, CHUQ, 11 Côte du Palais, Québec, Québec G1R 2J6, Canada.

出版信息

Med Phys. 2008 May;35(5):1970-7. doi: 10.1118/1.2900722.

Abstract

The robustness of treatment planning to prostatic edema for three different isotopes (125I, 103Pd, and 131Cs) is explored using dynamical dose calculations on 25 different clinical prostate cases. The treatment plans were made using the inverse planning by simulated annealing (IPSA) algorithm. The prescription was 144, 127, and 125 Gy for 125I, 131Cs, and 103Pd, respectively. For each isotope, three dose distribution schemes were used to impose different protection levels to the urethra: V120 = 0%, V150 = 0%, and V150 = 30%. Eleven initial edema values were considered ranging from 1.0 (no edema) to 2.0 (100%). The edema was assumed to resolve exponentially with time. The prostate volume, seed positions, and seed activity were dynamically tracked to produce the final dose distribution. Edema decay half-lives of 10, 30, and 50 days were used. A total of 675 dynamical calculations were performed for each initial edema value. For the 125I isotope, limiting the urethra V120 to 0% leads to a prostate D90 under 140 Gy for initial edema values above 1.5. Planning with urethra V150 at 0% provides a good response to the edema; the prostate D90 remains higher than 140 Gy for edema values up to 1.8 and a half-life of 30 days or less. For 103Pd, the prostate D90 is under 97% of the prescription dose for approximately 66%, 40%, and 30% of edema values for urethra V120 = 0%, V150 = 0%, and V150 = 30%, respectively. Similar behavior is seen for 131Cs and the center of the prostate becomes "cold" for almost all edema scenarios. The magnitude of the edema following prostate brachytherapy, as well as the half-life of the isotope used and that of the edema resorption, all have important impacts on the dose distribution. The 125I isotope with its longer half-life is more robust to prostatic edema. Setting up good planning objectives can provide an adequate compromise between organ doses and robustness. This is even more important since seed misplacements will contribute to further degrade dose coverage.

摘要

利用对25个不同临床前列腺病例的动态剂量计算,探讨了三种不同同位素(125I、103Pd和131Cs)治疗计划对前列腺水肿的稳健性。治疗计划采用模拟退火逆向规划(IPSA)算法制定。125I、131Cs和103Pd的处方剂量分别为144、127和125 Gy。对于每种同位素,使用三种剂量分布方案对尿道施加不同的保护水平:V120 = 0%、V150 = 0%和V150 = 30%。考虑了11个初始水肿值,范围从1.0(无水肿)到2.0(100%)。假设水肿随时间呈指数衰减。动态跟踪前列腺体积、籽源位置和籽源活度以产生最终剂量分布。使用了10、30和50天的水肿衰减半衰期。对于每个初始水肿值,总共进行了675次动态计算。对于125I同位素,当初始水肿值高于1.5时,将尿道V120限制在0%会导致前列腺D90低于140 Gy。将尿道V150设定为0%进行规划对水肿有良好的反应;对于水肿值高达1.8且半衰期为30天或更短的情况,前列腺D90仍高于140 Gy。对于103Pd,当尿道V120 = 0%、V150 = 0%和V150 = 30%时,前列腺D90分别在约66%、40%和30%的水肿值下低于处方剂量的97%。131Cs也有类似情况,在几乎所有水肿情况下前列腺中心都会变“冷”。前列腺近距离治疗后的水肿程度、所用同位素的半衰期以及水肿吸收的半衰期,都对剂量分布有重要影响。半衰期较长的125I同位素对前列腺水肿更具稳健性。设定良好的规划目标可以在器官剂量和稳健性之间提供适当的折衷。由于籽源放置不当会导致剂量覆盖进一步下降,这一点更为重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验